olaparib,bevacizumab
Merck,Astrazeneca
['gyn', 'bevacizumab', 'vance', 'olaparib', 'ovarian']
olaparib plus bevacizumab maintenance therapy after treatment with the first-line standard-of-care led to a clinically meaningful improvement in os in patients with advanced ovarian cancer and hrd. #esmo2022 #gyncsm | 
Oncology news and insights from leading researchers and cancer centers.